EPILEPSY TORONTO
What's New
in Epilepsy

DRUG DISCONTINUATION ALERT: DEPAKENE®

BGP Pharma ULC has posted a notice that DEPAKENE® (valproic acid) capsules (250 mg; DIN 00443840) have been discontinued effective April 24, 2017. https://www.drugshortagescanada.ca/discontinuance/8402

This product has been in shortage since January, so stock levels have been depleted over the past few months. Some pharmacies may still have a small amount on hand but may not be able to replenish what they have. Other pharmacies may already be out-of-stock.

Anyone currently taking Depakene capsules should discuss their treatment options with their healthcare provider. People should work closely with their pharmacist and healthcare provider during the transition from Depakene capsules to an alternate treatment and notify their healthcare provider if they experience side-effects or changes in seizure control.

Update: There are generic forms of valproic acid capsules on the market. Here are the ones listed in the Health Canada drug product database:
 
Marketed 02238048
APOTEX INC APO-VALPROIC VALPROIC ACID 250 MG
 
Marketed 02231030
DOMINION PHARMACAL DOM-VALPROIC ACID VALPROIC ACID 250 MG
 
Marketed 02100630
TEVA CANADA LIMITED NOVO-VALPROIC VALPROIC ACID 250 MG
 
Marketed 02230768
PHARMASCIENCE INC PMS-VALPROIC ACID VALPROIC ACID 250 MG
 
Marketed 02217414
TEVA CANADA LIMITED RATIO-VALPROIC VALPROIC ACID 250 MG
 
Marketed 02239714
SANDOZ CANADA INCORPORATED SANDOZ VALPROIC VALPROIC ACID 250 MG
Print Friendly, PDF & Email